Clinical Trials

Phase 2 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03937830 2026-03-24

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

27 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

301 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05128032 2026-03-19

PEDIR

20 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms

NCT06040099 2026-03-19

EMERALD-Y90

58 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03028311 2026-03-10

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

12 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05743842 2026-03-09

TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning

19 enrolled

Phase 1/2 Active not recruiting

Liver Neoplasms

NCT06084884 2026-03-09

ATHENA

94 enrolled

Phase 3 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03847428 2026-03-06

EMERALD-2

908 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05103631 2026-03-06

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

GastrointestinalGenitourinarySarcoma

12 enrolled

Carcinoma, Hepatocellular, Liposarcoma, Liver Neoplasms, Wilms Tumor, Rhabdomyosarcoma, Endodermal Sinus Tumor, Rhabdoid Tumor

NCT05953337 2026-03-04

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

120 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT05438420 2026-02-24

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

120 enrolled

GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Stomach Neoplasms

NCT04258813 2026-02-20

ONE TEAM

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

313 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Cardiovascular Diseases, Colonic Neoplasms, Diabetes Mellitus, Esophageal Neoplasms, Head and Neck Neoplasms, Hypercholesterolemia, Hypertension, Liver Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT05883644 2026-02-18

SIERRA

Phase 3 Active not recruiting

111 enrolled

Liver Neoplasms

NCT04736121 2026-02-03

DOORwaY90

100 enrolled

Liver Neoplasms

NCT07362264 2026-01-23

A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors

50 enrolled

Liver Neoplasms

NCT04377932 2026-01-21

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors